Can NAT2, EPHX1, and CYP1B1 variants increase vulnerability to chemical exposure?

Individual susceptibility to environmental toxicants is heavily governed by genetic variations within Phase I and Phase II detoxification pathways, which dictate how efficiently the body biotransforms and clears foreign compounds.

Genetic modulation of detoxification pathways

Functional variations in CYP1B1, EPHX1, and NAT2 enzymes directly alter metabolic kinetics:

• CYP1B1 (Phase I): The rs1056836 (Leu432Val) polymorphism alters estradiol hydroxylation kinetics, with the Val432 variant exhibiting an altered, often higher, 4-hydroxylase clearance capacity.
• EPHX1 (Phase I/II boundary): The rs1051740 (Tyr113His) variant reduces microsomal epoxide hydrolase activity by 40% to 50%, whereas the rs2234922 (His139Arg) variant increases this activity by approximately 25%.
• NAT2 (Phase II): The rs1801280 (p.Ile114Thr) and rs1799930 (p.Arg197Gln) loss-of-function alleles impair CoA binding and substrate processing, resulting in a slow acetylator phenotype characterized by reduced clearance rates.

Impact of high chemical exposure

Impaired enzymatic clearance networks dynamically interact with xenobiotic burdens, leading to elevated toxicity and tissue damage:

• Genotoxicity and oxidative stress: NAT2 slow acetylators experience significantly elevated DNA damage and systemic toxicity when exposed to organophosphate pesticides. Similarly, EPHX1 variants modify susceptibility to DNA damage and oxidative stress under pesticide exposure.
• Organ-specific susceptibility: Slow NAT2 acetylators carrying loss-of-function variants show a significantly higher risk of drug-induced hepatotoxicity and liver injury.
• Receptor-mediated risk: CYP1B1 variants demonstrate pronounced associations with heightened genotoxic risk and breast cancer susceptibility under high exposure to organochlorine hydrocarbons and agricultural pollutants, which actively induce the enzyme via aryl hydrocarbon receptor (AhR) signaling.

Bottom line

• Genetic polymorphisms in CYP1B1, EPHX1, and NAT2 alter Phase I and Phase II metabolic kinetics, directly translating to elevated risks of DNA damage, hepatotoxicity, and systemic oxidative stress when chemical exposure burdens—particularly from organophosphate and organochlorine pesticides—are high.